Skip to main content
BRTX
NASDAQ Industrial Applications And Services

Former Auditor Flags Potential Reportable Event Tied to Product Suspension

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.707
Mkt Cap
$3.812M
52W Low
$2.61
52W High
$34.6
52W Position info
3.7% above low
Off High info
92% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BRTX is trading near its 52-week low of $2.61 (3.7% above the low).

Summary

BioRestorative's former auditor CBIZ flagged a potential reportable event related to the company's suspended biocosmeceutical product lines, and the audit committee has launched an independent investigation. The company also engaged Bush & Associates CPA to re-audit fiscal years 2024 and 2025.


Key Events · Legal and Risk Events · BRTX

  • Former Auditor Flags Reportable Event

    CBIZ CPAs informed the company that a reportable event may exist under Item 304(a)(1)(v)(C) because the biocosmeceutical product suspension and related reviews involve information that, if further investigated, may materially impact the reliability of previously issued financial statements.

  • Audit Committee Investigation Ongoing

    The audit committee hired an independent investigator on August 14, 2026, to examine the circumstances leading up to the product suspension. The investigation is ongoing and has not yet uncovered material information not previously reported.

  • New Auditor to Re-Audit Prior Years

    Bush & Associates CPA was engaged effective August 28, 2026, to perform new audits of fiscal years 2025 and 2024, in addition to the fiscal year ending December 31, 2026.

  • CBIZ Letter Filed as Exhibit

    CBIZ provided a letter to the SEC stating it agrees with the statements concerning its firm in the 8-K/A, but is not in a position to agree or disagree with other statements.


Analysis · BRTX · Industrial Applications And Services

The amendment reveals that CBIZ CPAs, the auditor dismissed on August 28, 2026, has informed the company that a 'reportable event' may exist because the suspension of its biocosmeceutical product lines and related reviews involve information that, if further investigated, may materially impact the reliability of previously issued financial statements. CBIZ has not concluded that any prior financial statements should not be relied upon, but the company's audit committee has hired an independent investigator and the matter remains unresolved. This adds a new layer of accounting and regulatory risk to a company already facing a Nasdaq delisting notice, a going-concern warning, and a recent reverse stock split.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRTX was trading at $2.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $2.61 to $34.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRTX - Latest Insights

BRTX
Sep 02, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
BRTX
Sep 02, 2026, 5:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
BRTX
Sep 01, 2026, 6:09 PM EDT
Filing Type: 8-K
Importance Score:
8
BRTX
Aug 25, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
BRTX
Aug 14, 2026, 4:47 PM EDT
Source: Reuters
Importance Score:
8